Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early clinical study group (ECSG)

S Aamdal, B Lund, I Koier, M Houten, J Wanders, Jaap Verweij

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)85-88
Number of pages4
JournalCancer Chemotherapy & Pharmacology
Volume45
Publication statusPublished - 2000

Research programs

  • EMC MM-03-86-08

Cite this